Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rituximab therapy for treatment of chronic humoral rejection (CHR). [Abstract #991]

Rituximab therapy for treatment of chronic humoral rejection (CHR). [Abstract #991]. Am J Transplant. 2008; 8(Suppl 2):443.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.